Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC009550 | Panoply™ Human MKRN3 Knockdown Stable Cell Line | Inquiry |
| CSC-SC009550 | Panoply™ Human MKRN3 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD09984Z | Human MKRN3 adenoviral particles | Inquiry |
| LV18303L | human MKRN3 (NM_005664) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH342352 | shRNA set against Human MKRN3 (NM_005664.3) | Inquiry |
| SHH342356 | shRNA set against Mouse MKRN3 (NM_011746.2) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| MiUTR1M-07139 | MKRN3 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-06316 | MKRN3 miRNA 3'UTR clone | Inquiry |
| CDCB192056 | Rabbit MKRN3 ORF clone (XM_002718286.2) | Inquiry |
| CDCL132909 | Human Mkrn3 ORF clone (NM_011746.2) | Inquiry |
| CDCS412358 | Human MKRN3 ORF Clone (BC044639) | Inquiry |
| CDCS412359 | Human MKRN3 ORF Clone (BC070293) | Inquiry |
The MKRN3 gene (makorin RING-finger protein 3) is at a critical position in the Prader-Willi syndrome (on chromosome 15q11.2). Prader-Willi syndrome is a genetic disorder characterized by decreased muscle tone in infancy and an increase in appetite, hypogonadism, growth hormone deficiency, mental retardation, and severe emotional behavioral disorders with age. Although MKRN3 is at a critical position in Prader-Willi syndrome, the relationship between MKRN3 and Prader-Willi syndrome is unclear. So far, humans have found 21 mutations in the MKRN3 gene: including 8 frameshift mutations, 10 missense mutations, and 3 nonsense mutations.
Figure 1. Schematic representation of MKRN3 mechanism of action.(Abreu, A. P., et al.2015)
Relationship Between Central Precocious Puberty and MKRN3
Abreu et al. sequenced the entire exon in 32 patients with central precocious puberty and 8 healthy individuals with a history of precocious puberty. Four new MKRN3 heterozygous mutations were found. Patients with MKRN3 mutations and central precocious puberty inherited mutations from their fathers, and those who inherited MKRN3 mutations from their mothers did not exhibit precocious puberty. This suggests that MKRN3 may be a maternal imprinting gene, which is expressed only by paternal inheritance. Additional studies support this view and suggest that MKRN3 may inhibit targets downstream of the HPG axis rather than activating GnRH neurons. In one study, the researchers performed MKRN3 gene sequencing on 215 patients with central precocious puberty and found five new heterozygous mutations in eight patients, all of which were genetically inherited from the father. The idea that MKRN3 is a maternal imprinted gene is also demonstrated.
Association of MKRN3 with Familial Central Precocious Puberty
In one case analysis, a new MKRN3 heterozygous missense mutation (p.c340g) was found in a girl with central precocious puberty and a younger brother with early development. The mutation was also tested in their father and grandmother. The investigators hypothesized that if a family has a history of central precocious puberty or early adolescence, it can be considered as a mutation in MKRN3. Abreu et al. also suggested that the loss of function of MKRN3 mutations may lead to familial central precocious puberty. A total of 46 patients with central precocious puberty were enrolled in the study (28 patients had a history of familial precocious puberty and 18 patients had a family history of asexual precocity). MKRN3 gene mutations were detected in 13 patients with a history of familial precocious puberty.
The researchers sequenced the MKRN3 gene in 60 girls with idiopathic central precocious puberty (23 girls with a family history of precocious puberty), and obtained three MKRN3 gene mutations, p.Arg328Cys, p.Cys410Ter, p.Pro160Cysfs*14, wherein p.Cys410Ter is a novel mutation. These mutations are inherited from the patient's father. The investigator followed a 4-year-old girl with a history of familial precocious puberty. The girl's sister was diagnosed with central precocious puberty at the age of 6 and carried the p. Pro161Argfs*16 mutation inherited from her father. The girl who was followed was experiencing an accelerated rate of growth (9 cm/year) at age 6 and between 6.3 and 6.7 years of age, breast development progressed rapidly (Tanner1-Tanner3) with an elevated LH baseline ( 0.4 IU/L), the girl was quickly diagnosed with precocious puberty and treated.
References: